Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to Cofrogliptin from Daily DPP-4i in T2DM
NCT06703268Phase 2Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Jan 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cofrogliptin in type 2 diabetes mellitus (T2DM), sponsored by Haisco Pharmaceutical Group Co., Ltd.. Started Jan 2024; status: completed.
02
Drugs
cofrogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06703268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06703268.